Journal of Literature Pharmacy Sciences

CRISPR/Cas 9 Temelli Teknolojilerin Farmakoloji Alanında Uygulamaları: Geleneksel Derleme
Applications of CRISPR/Cas 9 Based Technologies in the Field of Pharmacology: A Traditional Review
Sena USTAÖMERa, Yeşim KAYA YAŞARb
aKaradeniz Teknik Üniversitesi Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Trabzon, Türkiye
bKaradeniz Teknik Üniversitesi Eczacılık Fakültesi, Farmakoloji ABD, Trabzon, Türkiye
J Lit Pharm Sci. 2023;12(3):210-9
doi: 10.5336/pharmsci.2023-96500
Article Language: TR
Full Text
ÖZET
 RNA tabanlı nükleaz sistemi olan CRISPR (clustered regularly interspaced short palindromic repeats) temelli genom düzenleme teknolojisi, bakterilerin plazmit veya nükleik asit içeren viral kapsidlere karşı geliştirdiği direnç mekanizmalarından biridir. CRISPR/Cas sistemi yabancı DNA'ya ait küçük DNA parçalarının prokaryotik hücrenin genomuna katılmasını sağlar. Böylece konakçı hücrenin aynı istilacı ile yeniden karşılaşması durumunda, adaptif bağışık yanıt devreye girer. CRISPR/Cas sistemi çeşitli viral vektörler ve lipid partiküller gibi taşıyıcı sistemler ile biyolojik ortamlara uygulanarak hücrelerin genomunda değişiklik yapılmasını sağlar. Bu nedenle CRISPR/Cas sistemi beta talasemi, orak hücreli anemi, duchenne kas distrofisi, transtiretin amiloidosis ve Leber konjenital amorozisi gibi hastalıklarda genomda mutasyondan etkilenen bölgeyi düzeltmek amacıyla kanser gibi hastalıklarda ise terapötik strateji olarak preklinik ve klinik çalışmalarda değerlendirilmektedir. Makalede CRISPR/Cas sistemi açıklanarak; literatürde bu sistemin biyolojik ortamlara uygulandığı, genetik hastalıklar ve kanser gibi çeşitli klinik durumların tedavisinde etkinliği ve güvenilirliğinin değerlendirildiği araştırmaların sonuçları sistematik şekilde derlenerek sunulmuştur.

Anahtar Kelimeler: CRISPR/Cas sistem; taşıyıcı sistemler; pre-klinik/klinik çalışmalar
ABSTRACT
 CRISPR (clustered regularly interspaced short palindromic repeats)-based genome technology, which is an RNA-based nuclease system, is one of the resistance mechanisms developed by bacteria against viral capsids containing plasmid or nucleic acid. The CRISPR/Cas system provides that small DNA fragments of foreign DNA to be integrated into the genome of the prokaryotic cell and the adaptive immune response is activated when the host cell encounters the same invader again. The CRISPR/Cas system can be applied to biological systems with various vehicle systems such as viral vectors and lipid particles, allowing modifications to the genome of cellThus, in the event that the host cell encounters the same invader again, the adaptive immune response is activated. Furthermore, in order to correct the region affected by mutation in the genome in diseases such as beta thalassemia, sickle cell anemia, duchenne muscular dystrophy, transthyretin amyloidosis and leber congenital amorosis and also in cancer, CRISPR system is evaluated in preclinical and clinical studies as a therapeutic strategy. In this article, by explaining the CRISPR/Cas system, it was reviewed and presented the results of the studies in which this system was applied to biological environments and the effectiveness and safety of the treatment of various clinical conditions such as genetic diseases and cancer in the literature.

Keywords: CRISPR/Cas systems; vehicle systems; preclinical and clinical studies
REFERENCES:
  1. Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol. 1987;169(12):5429-33. [Crossref]  [PubMed]  [PMC] 
  2. Jansen R, van Embden JD, Gaastra W, Schouls LM. Identification of a novel family of sequence repeats among prokaryotes. OMICS. 2002;6(1):23-33. [Crossref]  [PubMed] 
  3. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology (Reading). 2005;151(Pt 8):2551-61. [Crossref]  [PubMed] 
  4. Garneau JE, Dupuis MÈ, Villion M, Romero DA, Barrangou R, Boyaval P, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010;468(7320):67-71. [Crossref]  [PubMed] 
  5. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. [Crossref]  [PubMed] 
  6. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-21. [Crossref]  [PubMed]  [PMC] 
  7. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471. [Crossref]  [PubMed]  [PMC] 
  8. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539(7630):479. [Crossref]  [PubMed] 
  9. Uyhazi KE, Bennett J. A CRISPR view of the 2020 nobel Prize in Chemistry. J Clin Invest. 2021;131(1):e145214. [Crossref]  [PubMed]  [PMC] 
  10. Deveau H, Barrangou R, Garneau JE, Labonté J, Fremaux C, Boyaval P, et al. Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol. 2008;190(4):1390-400. [Crossref]  [PubMed]  [PMC] 
  11. Mojica FJM, Díez-Villaseñor C, García-Martínez J, Almendros C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (Reading). 2009;155(Pt 3):733-40. [Crossref]  [PubMed] 
  12. Hao M, Cui Y, Qu X. Analysis of CRISPR-Cas System in Streptococcus thermophilus and Its application. Front Microbiol. 2018;9:257. [Crossref]  [PubMed]  [PMC] 
  13. Wiedenheft B, Sternberg SH, Doudna JA. RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012;482(7385):331-8. [Crossref]  [PubMed] 
  14. Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015;33(9):985-9. [Crossref]  [PubMed]  [PMC] 
  15. Li Y, Glass Z, Huang M, Chen Zy, Xu Q. Ex vivo cell-based CRISPR/Cas9 genome editing for therapeutic applications. Biomaterials. 2020;234:119711. [Crossref]  [PubMed]  [PMC] 
  16. Stout E, Klaenhammer T, Barrangou R. CRISPR-cas technologies and applications in food bacteria. Annu Rev Food Sci Technol. 2017;8:413-37. [Crossref]  [PubMed] 
  17. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPRCas9 for genome engineering. Cell. 2014;157(6):1262-78. [Crossref]  [PubMed]  [PMC] 
  18. Li B, Niu Y, ji W, Dong Y. Strategies for the CRISPR-Based therapeutics. trends Pharmacol Sci. 2020;41(1):55-65. [Crossref]  [PubMed]  [PMC] 
  19. Sanozky-Dawes R, Selle K, O'flaherty S, Klaenhammer T, Barrangou R. Occurrence and activity of a type II CRISPR-Cas system in Lactobacillus gasseri. Microbiology (Reading). 2015;161(9):1752-61. [Crossref]  [PubMed] 
  20. Barrangou R, Horvath P. CRISPR: new horizons in phage resistance and strain identification. Annu Rev Food Sci Technol. 2012;3:143-62. [Crossref]  [PubMed] 
  21. Bauer DE, Canver MC, Orkin SH. Generation of genomic deletions in mammalian cell lines via CRISPR/Cas9. J Vis Exp. 2015;(95):e52118. [Crossref]  [PubMed]  [PMC] 
  22. ClinicalTrials [Internet]. [Cited: March 30, 2022]. Gene correction in autologous CD34+ hematopoietic stem cells (HbS to HbA) to treat severe sickle cell disease (CEDAR). Available from: [Link] 
  23. Saraf SL, Molokie RE, Nouraie M, Sable CA, Luchtman-Jones L, Ensing GJ, et al. Differences in the clinical and genotypic presentation of sickle cell disease around the world. Paediatr Respir Rev. 2014;15(1):4-12. [Crossref]  [PubMed]  [PMC] 
  24. Bauer DE, Kamran SC, Lessard S, Xu J, Fujiwara Y, Lin C, et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science. 2013;342(6155):253-7. [Crossref]  [PubMed]  [PMC] 
  25. ClinicalTrials [Internet]. [Cited: March 30, 2022]. A safety and efficacy study evaluating CTX001 in subjects with transfusion-dependent β-thalassemia. Available from: [Link] 
  26. ClinicalTrials [Internet]. [Cited: March 30, 2022]. A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. Available from: [Link] 
  27. ClinicalTrials [Internet]. [Cited: March 30, 2022]. Safety and efficacy evaluation of γ-globin reactivated autologous hematopoietic stem cells. Available from: [Link] 
  28. Min YL, Bassel-Duby R, Olson EN. CRISPR correction of duchenne muscular dystrophy. Annu Rev Med. 2019;70:239-55. [Crossref]  [PubMed]  [PMC] 
  29. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823-6. [Crossref]  [PubMed]  [PMC] 
  30. Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625-38. [Crossref]  [PubMed]  [PMC] 
  31. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 In Vivo gene Editing for transthyretin amyloidosis. N Engl J Med. 2021;385(6):493-502. [Crossref]  [PubMed] 
  32. ClinicalTrials [Internet]. [Cited: May 11, 2022]. Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ntLa-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM). Available from: [Link] 
  33. Dohrn MF, Ihne S, Hegenbart U, Medina J, Züchner SL, Coelho T, et al. Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. J Neurochem. 2021;156(6):802-18. [Crossref]  [PubMed] 
  34. Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. [Crossref]  [PubMed] 
  35. Adams D, Gonzalez-Duarte A, O'riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. [PubMed] 
  36. Gillmore JD, Maitland ML, Lebwohl D. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. Reply. N Engl J Med. 2021;385(18):1722-3. [Crossref]  [PubMed] 
  37. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2015;112(1):118-23. [Crossref]  [PubMed]  [PMC] 
  38. Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26(5):732-740. Erratum in: Nat Med. 2020;26(7):1149. [Crossref]  [PubMed] 
  39. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumorassociated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793-800. Erratum in: Nat Med 2002;8(9):1039. [Crossref]  [PubMed] 
  40. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64. [Crossref]  [PubMed]  [PMC] 
  41. Jo DH, Song DW, Cho CS, Kim UG, Lee KJ, Lee K, et al. CRISPR-Cas9-mediated therapeutic editing of Rpe65 ameliorates the disease phenotypes in a mouse model of Leber congenital amaurosis. Sci Adv. 2019;5(10):eaax1210. [Crossref]  [PubMed]  [PMC] 
  42. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res. 2010;29(5):398-427. [Crossref]  [PubMed]  [PMC] 
  43. Editasmedicine [Internet]. ©Copyright 2022 Editas Medicine [Cited: May 11, 2022]. PRESS RELEASE Editas Medicine announces Dosing of first Pediatric Patient in the BRILLIANCE Clinical Trial Of EDIT-101 For LCA10. Available from: [Link] 
  44. Sahel DK, Mittal A, Chitkara D. CRISPR/cas system for genome editing: progress and prospects as a therapeutic tool. J Pharmacol Exp Ther. 2019;370(3):725-35. [Crossref]  [PubMed] 
  45. Chew WL, Tabebordbar M, Cheng JK, Mali P, Wu EY, Ng AH, et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. 2016;13(10):868-74. [Crossref]  [PubMed]  [PMC] 
  46. Ruan GX, Barry E, Yu D, Lukason M, Cheng SH, Scaria A. CRISPR/Cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10. Mol Ther. 2017;25(2):331-41. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com